Insider · CIK 0001779805

Young Jonathan

Reports to the SEC for 1 company · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001779805

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-12-09	Akero Therapeutics, Inc.D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−153K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−20K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−20K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−20K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−47.6K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−3,421 sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−5,032 sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−2,328 sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−70.3K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−141K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−84.1K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−29.1K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−29.1K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−45K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−28.6K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−74.1K sh	—	—	0
2025-11-26	Akero Therapeutics, Inc.G Gift	Chief Operating Officer	GGift	−9,259 sh	—	—	200,189
2025-11-24	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+4,284 sh	$21.09	+$90.3K	201,182
2025-11-24	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+3,527 sh	$28.35	+$100K	204,709
2025-11-24	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+4,739 sh	$21.10	+$100K	209,448
2025-11-24	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−4,284 sh	—	—	0
2025-11-24	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−3,527 sh	—	—	0
2025-11-24	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−4,739 sh	—	—	0
2025-10-01	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+12.5K sh	$21.10	+$264K	209,398
2025-10-01	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−8,299 sh	$47.64	−$395K	201,099
2025-10-01	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−4,201 sh	$47.98	−$202K	196,898
2025-10-01	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−12.5K sh	—	—	44,982
2025-09-11	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−586 sh	$43.02	−$25.2K	196,898
2025-09-02	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+12.5K sh	$21.10	+$264K	209,984
2025-09-02	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−9,700 sh	$45.78	−$444K	200,284
2025-09-02	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−2,739 sh	$47.14	−$129K	197,545
2025-09-02	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−61 sh	$47.58	−$2,902.38	197,484
2025-09-02	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−12.5K sh	—	—	57,482
2025-08-12	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+12.5K sh	$21.10	+$264K	209,984
2025-08-12	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−11.2K sh	$47.72	−$532K	198,833
2025-08-12	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−1,349 sh	$48.32	−$65.2K	197,484
2025-08-12	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−12.5K sh	—	—	69,982
2025-06-30	Akero Therapeutics, Inc.A Award	Chief Operating Officer	AAward	+890 sh	$23.87	+$21.2K	197,484
2025-06-18	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−1,453 sh	$54.84	−$79.7K	196,594
2025-06-10	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−2,493 sh	$53.99	−$135K	198,047
2025-03-12	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−607 sh	$44.88	−$27.2K	200,540
2025-03-04	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−11.4K sh	$44.17	−$506K	239,700
2025-03-04	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−38.6K sh	$45.07	−$1.74M	201,147
2025-02-03	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−5,100 sh	$53.56	−$273K	256,047
2025-02-03	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−4,900 sh	$54.06	−$265K	251,147
2025-01-24	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+43.1K sh	$6.36	+$274K	261,147
2025-01-23	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−43.1K sh	—	—	0
2025-01-02	Akero Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−10K sh	$28.03	−$280K	218,083
2024-12-16	Akero Therapeutics, Inc.A Award	Chief Operating Officer	AAward	+24.3K sh	—	—	228,083
2024-12-16	Akero Therapeutics, Inc.Stock Option (Right to Buy)A Award	Chief Operating Officer	AAward	+73.7K sh	—	—	73,700

Recent filings

Accepted (ET)
Dec 94
Young Jonathan0001193125-25-312092
SEC(opens sec.gov)
Nov 264
Young Jonathan0001193125-25-300488
SEC(opens sec.gov)

Companies

Akero Therapeutics, Inc.Chief Operating Officer

Address

C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350

SOUTH SAN FRANCISCO, CA, 94080